Table 4 Adverse events.

From: Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM)

Adverse event, # (%)

Verum (n = 259)

Sham (n = 279)

Total (N = 538)

P

Verum (n = 207)

Sham (n = 231)

Total (N = 438)

P

Forehead paresthesias, discomfort or burning

9 (3.5)

1 (0.4)

10 (1.9)

0.009

4 (1.9)

1 (0.4)

5 (1.1)

0.194

Nausea/vomiting

4 (1.5)

0 (0.0)

4 (0.7)

0.053

3 (1.4)

0 (0.0)

3 (0.7)

0.105

Dizziness

1 (0.4)

2 (0.7)

3 (0.6)

1.000

1 (0.5)

1 (0.4)

2 (0.5)

1.000

Neck stiffness/muscle tension

1 (0.4)

2 (0.7)

3 (0.6)

1.000

1 (0.5)

2 (0.9)

3 (0.7)

1.000

Worsened headache

2 (0.8)

0 (0.0)

2 (0.4)

0.231

0 (0.0)

0 (0.0)

0 (0.0)

Orodynia—tooth or jaw pain

1 (0.4)

1 (0.4)

2 (0.4)

1.000

0 (0.0)

1 (0.4)

1 (0.2)

1.000

Restlessness

1 (0.4)

1 (0.4)

2 (0.4)

1.000

1 (0.5)

1 (0.4)

2 (0.5)

1.000

Abdominal discomfort or cramping

0 (0.0)

2 (0.7)

2 (0.4)

0.500

0 (0.0)

0 (0.0)

0 (0.0)

Dry mouth

1 (0.4)

0 (0.0)

1 (0.2)

0.481

1 (0.5)

0 (0.0)

1 (0.2)

0.473

Excessive sweating

2 (0.8)

0 (0.0)

2 (0.4)

0.231

2 (1.0)

0 (0.0)

2 (0.5)

0.223

Sedation/sleepiness

1 (0.4)

0 (0.0)

1 (0.2)

0.481

1 (0.5)

0 (0.0)

1 (0.2)

0.473

Total patients with an adverse effect

22 (8.5)

8 (2.9)

30 (5.6)

0.004

14 (6.8)

5 (2.2)

19 (4.3)

0.018

  1. Fisher’s exact test is used for all comparisons due to cell counts < 5, and therefore X2 statistic is not presented. ‘Total patients with an adverse effect’ does not add up to the total number of adverse effects in separate categories due to one patient in each group having two adverse events.